绿帽社

绿帽社 Pharma joins The Liver Forum

Published on 12/12/2017

绿帽社 Pharma is pleased to join The Liver Forum at the Forum for Collaborative Research, 鈥渢o advance the regulatory sciences for the treatment of NASH and liver fibrosis, which is emerging as a leading cause of advanced liver disease in the U.S. and worldwide鈥� (http://www.forumresearch.org/projects/liver-forum). The Liver Forum provides an independent and neutral venue for ongoing multi-stakeholder dialogue. This project will allow our biotech to participate in fruitful meetings and discussions focused on advancing the regulatory sciences for the treatment of NASH and liver fibrosis.

Read next in 'Latest news'

• Enrollment completed for our Phase 2 clinical trial in Alport syndrome
• The first patient dosed in the Phase 2 ALPESTRIA-1 clinical study of Vonafexor for Alport syndrome
• The Phase 2 ALPESTRIA-1 clinical study has started with Vonafexor on Alport syndrome
• Orphan Drug Designation (ODD) granted to Vonafexor for Alport syndrome by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA)
• New publication: Hepatic and renal improvements with FXR agonist Vonafexor in individuals with suspected fibrotic NASH